296 related articles for article (PubMed ID: 22079466)
1. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma.
Piao LS; Hur W; Kim TK; Hong SW; Kim SW; Choi JE; Sung PS; Song MJ; Lee BC; Hwang D; Yoon SK
Cancer Lett; 2012 Feb; 315(2):129-37. PubMed ID: 22079466
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia promotes radioresistance of CD133-positive Hep-2 human laryngeal squamous carcinoma cells in vitro.
Wang M; Li X; Qu Y; Xu O; Sun Q
Int J Oncol; 2013 Jul; 43(1):131-40. PubMed ID: 23652853
[TBL] [Abstract][Full Text] [Related]
3. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.
Zhang L; Li H; Ge C; Li M; Zhao FY; Hou HL; Zhu MX; Tian H; Zhang LX; Chen TY; Jiang GP; Xie HY; Cui Y; Yao M; Li JJ
Oncotarget; 2014 Nov; 5(21):10621-35. PubMed ID: 25301737
[TBL] [Abstract][Full Text] [Related]
5. Latexin inhibits the proliferation of CD133+ miapaca-2 pancreatic cancer stem-like cells.
Xue ZX; Zheng JH; Zheng ZQ; Cai JL; Ye XH; Wang C; Sun WJ; Zhou X; Lu MD; Li PH; Cai ZZ
World J Surg Oncol; 2014 Dec; 12():404. PubMed ID: 25551472
[TBL] [Abstract][Full Text] [Related]
6. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
[TBL] [Abstract][Full Text] [Related]
7. High expression of HIF-2α and its anti-radiotherapy effect in lung cancer stem cells.
Sun JC; He F; Yi W; Wan MH; Li R; Wei X; Wu R; Niu DL
Genet Mol Res; 2015 Dec; 14(4):18110-20. PubMed ID: 26782458
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
[TBL] [Abstract][Full Text] [Related]
9. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.
Tang KH; Ma S; Lee TK; Chan YP; Kwan PS; Tong CM; Ng IO; Man K; To KF; Lai PB; Lo CM; Guan XY; Chan KW
Hepatology; 2012 Mar; 55(3):807-20. PubMed ID: 21994122
[TBL] [Abstract][Full Text] [Related]
10. Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells.
Liu YM; Li XF; Liu H; Wu XL
Oncol Rep; 2015 Dec; 34(6):2977-86. PubMed ID: 26370320
[TBL] [Abstract][Full Text] [Related]
11. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations.
Yang Z; Zhang L; Ma A; Liu L; Li J; Gu J; Liu Y
PLoS One; 2011; 6(12):e28405. PubMed ID: 22145042
[TBL] [Abstract][Full Text] [Related]
12. CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy.
Li J; Chen JN; Zeng TT; He F; Chen SP; Ma S; Bi J; Zhu XF; Guan XY
BMC Cancer; 2016 Jan; 16():15. PubMed ID: 26758620
[TBL] [Abstract][Full Text] [Related]
13. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.
Ma S; Chan KW; Lee TK; Tang KH; Wo JY; Zheng BJ; Guan XY
Mol Cancer Res; 2008 Jul; 6(7):1146-53. PubMed ID: 18644979
[TBL] [Abstract][Full Text] [Related]
14. CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy.
Ke CC; Liu RS; Yang AH; Liu CS; Chi CW; Tseng LM; Tsai YF; Ho JH; Lee CH; Lee OK
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):61-71. PubMed ID: 23081821
[TBL] [Abstract][Full Text] [Related]
15. IL-6 signaling promotes DNA repair and prevents apoptosis in CD133+ stem-like cells of lung cancer after radiation.
Chen Y; Zhang F; Tsai Y; Yang X; Yang L; Duan S; Wang X; Keng P; Lee SO
Radiat Oncol; 2015 Nov; 10():227. PubMed ID: 26572130
[TBL] [Abstract][Full Text] [Related]
16. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
[TBL] [Abstract][Full Text] [Related]
17. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
[TBL] [Abstract][Full Text] [Related]
18. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
19. Biology and clinical implications of CD133(+) liver cancer stem cells.
Ma S
Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
[TBL] [Abstract][Full Text] [Related]
20. Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment.
Song YJ; Zhang SS; Guo XL; Sun K; Han ZP; Li R; Zhao QD; Deng WJ; Xie XQ; Zhang JW; Wu MC; Wei LX
Cancer Lett; 2013 Oct; 339(1):70-81. PubMed ID: 23879969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
